Market Research Report
Global Diabetic Retinopathy Market Size, Status and Forecast 2019-2025
|Published by||QYResearch||Product code||843479|
|Published||Content info||114 Pages
Delivery time: 2-3 business days
|Global Diabetic Retinopathy Market Size, Status and Forecast 2019-2025|
|Published: July 9, 2019||Content info: 114 Pages||
Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease.
Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.
In 2018, the global Diabetic Retinopathy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Diabetic Retinopathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Diabetic Retinopathy development in United States, Europe and China.
The key players covered in this study
Market segment by Type, the product can be split into
Market segment by Application, split into
Market segment by Regions/Countries, this report covers
The study objectives of this report are:
In this study, the years considered to estimate the market size of Diabetic Retinopathy are as follows:
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.